Bioventus
BVS· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -29.1% in FY2025
Robert E. Claypoole is the CEO of Bioventus and was paid $4.3M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $71
Executives3
See all- 1Robert E. ClaypoolePresident & Chief Executive OfficerFY2025
- 2Mark SingletonSenior Vice President & Chief Financial OfficerFY2025
- 3Anthony D'AdamioSenior Vice President & General CounselFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allBioventus paid its 3 named executives $7.6M in total in FY2025 (Dec). CEO Robert E. Claypoole was paid $4.3M of that.
| Name | |||
|---|---|---|---|
| Robert E. ClaypoolePresident & Chief Executive Officer | Not disclosed | Not disclosed | |
| Mark SingletonSenior Vice President & Chief Financial Officer | Not disclosed | Not disclosed | |
| Anthony D'AdamioSenior Vice President & General Counsel |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Bioventus. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- William A. HawkinsChair · 5 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Susan M. StalneckerDirector · 5 yr on the boardIndependentAudit and Risk (Chair), Compliance, Ethics and Culture—Paid as an executive
- Mary Kay LadoneDirector · 4 yr on the boardIndependentAudit and Risk, Compensation—Paid as an executive
- Michelle McMurry-HeathDirector · 3 yr on the boardIndependentCompliance, Ethics and Culture (Chair)—Paid as an executive
- John A. BartholdsonDirector · 2 yr on the boardIndependentCompensation (Chair), Compliance, Ethics and Culture—Paid as an executive
The board of the latest proxy (FY2025).
Shared directors
- BiogenWilliam A. Hawkins1 shared
- Leidos HoldingsSusan M. Stalnecker1 shared
- Mimedx GroupWilliam A. Hawkins1 shared
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Mar 11, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 12, 2024 | FY2023 |
